NeoGenomics Inc (NEO) Q3 2026 Earnings Call Highlights: Revenue Tops $209 Million as NGS
NeoGenomics Inc (NEO) reported Q3 2026 revenue of $209M, driven by 11% AUP growth from NGS products and RCM initiatives. CEO Tony Zook announced a transition to Warren Stone, emphasizing strategic alignment. The company expects continued AUP growth and slight pharma segment recovery in 2027, despite potential Medicare rate cuts. NGS volume growth is attributed to new products and sales force expansion.
How this was made
The 30-second read
Why it matters
The call emphasizes continued NGS mix shift and RCM gains supporting AUP growth, while positioning RADAR-ST as a workflow driver with a portfolio “halo.” It also provides a quantified magnitude for Medicare-rate exposure and a timeline for NovaSeq X margin benefits.
Market read
Traders can update expectations for NeoGenomics’ near-term AUP/margin trajectory based on management’s stated drivers, headwind magnitude, and timing of NovaSeq X benefits.
What to watch
RADAR-ST reimbursement expansion depends on pending indications; if reimbursement timing slips, the adoption and halo effects may not translate into faster revenue/margin than the market expects.
Background
The piece summarizes Q3 2026 earnings call Q&A for NeoGenomics, covering CEO succession, NGS/AUP drivers, RADAR-ST commercialization, Medicare rate-cut exposure, and margin trajectory.
Ticker impact
NeoGenomics’ Q3 2026 earnings call highlights include 11% AUP growth drivers, RADAR-ST adoption/halo effects, and exposure to preliminary 2027 Medicare rate cuts.
Likely upward bias as investors focus on NGS mix sustainability, RADAR-ST adoption momentum, and manageable Medicare-rate exposure.
The article provides multiple company-specific operational drivers (AUP, NGS volume, RADAR-ST ordering behavior) plus a quantified headwind range (low-to-mid single-digit millions) and a margin timing roadmap (NovaSeq X full impact in 2028).
Market effects
Reinforces demand signals for NGS-enabled oncology workflows and integrated test portfolios, which can influence sentiment across molecular diagnostics peers.
Primarily US-focused reimbursement and Medicare-rate sensitivity, with limited direct regional spillover beyond US healthcare/diagnostics sentiment.
Limited, as the disclosed reimbursement discussion is US Medicare-specific and the operational drivers are company-internal.
Counterpoint
The margin tailwind is explicitly gradual (NovaSeq X full impact in 2028) and unreimbursed MRD tests are a short-term headwind, which could temper near-term margin expectations.
Key entities
- companyNeoGenomics Inc
Discussed Q3 2026 performance drivers, RADAR-ST adoption strategy, Medicare rate-cut exposure, and margin trajectory into 2028.
- productRADAR-ST
Immunotherapy monitoring test whose IO indication promotion and reimbursement expansion are central to adoption and workflow embedding.
- business segmentOncology Data Solutions (ODS)
High-margin, double-digit growth opportunity tied to a growing genomics database for pharma partners.
